Flagship-backed biotech cuts nearly half its staff


A Flagship Pioneering spinout developing treatments for immune diseases is laying off 48 employees — about 45% of its staff.

Previous AmerisourceBergen invests $100M in $1.45B Project Black Fund targeting minority-led suppliers
Next Regis College awarded grant to continue work in Haiti